Status:

COMPLETED

Intravitreal Triamcinolone for Clinically Significant Diabetic Macular Oedema That Persists After Laser Treatment (TDMO)

Lead Sponsor:

University of Sydney

Conditions:

Diabetic Macular Oedema

Eligibility:

All Genders

18+ years

Phase:

PHASE2

PHASE3

Brief Summary

The trial will test the hypothesis that an intravitreal injection of triamcinolone is safe and efficacious for patients with clinically significant diabetic macular oedema that is recalcitrant to conv...

Detailed Description

Diabetic retinopathy is a common cause of severe loss of visual and the most common cause of legal blindness in individuals between the ages of 20 and 65 years in developed countries. Swelling of the ...

Eligibility Criteria

Inclusion

  • Clinically significant diabetic macular oedema involving the fovea in one or both eyes (phakic and/or pseudophakic) which persists at least 3 months after adequate macular photocoagulation.
  • best corrected visual acuity in the affected eye(s) 6/9 or worse

Exclusion

  • Glaucoma which is uncontrolled or is controlled but with glaucomatous visual field defects
  • Loss of vision due to other causes (e.g. age related macular degeneration, myopic macular degeneration)
  • Significant macular ischemia (FFA)
  • No useful vision in fellow eye
  • Known allergies to triamcinolone acetate or steroids
  • Patient is already under systemic treatment with \> 5mg prednisolone (or equivalent) daily.
  • Intercurrent severe disease such as septicaemia
  • Any condition which would affect follow-up or photographic documentation (e.g. geographical, psycho-social, media opacities)

Key Trial Info

Start Date :

March 1 2002

Trial Type :

INTERVENTIONAL

End Date :

April 1 2005

Estimated Enrollment :

70 Patients enrolled

Trial Details

Trial ID

NCT00167518

Start Date

March 1 2002

End Date

April 1 2005

Last Update

September 14 2005

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Save Sight Institute, Sydney/Sydney Eye Hospital Campus, University of Sydney

Sydney, New South Wales, Australia, 2000

Intravitreal Triamcinolone for Clinically Significant Diabetic Macular Oedema That Persists After Laser Treatment (TDMO) | DecenTrialz